#1 Clinical Trials Search in Europe

(S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid

This article discusses the clinical trials of a new topical medication, (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid gel, also known as N-Acetyl-GED-0507-34-Levo gel 5%, for the treatment of acne vulgaris. These trials aim to evaluate the safety and effectiveness of this new drug when applied once daily for various durations, ranging from 12 to 52 weeks. The studies include patients aged 9 to 50 years with facial and, in some cases, truncal acne vulgaris.

Table of Contents

What is N-Acetyl-GED-0507-34-LEVO Gel?

N-Acetyl-GED-0507-34-LEVO Gel is a new topical medication being studied for the treatment of acne vulgaris, which is the most common form of acne[1]. The active ingredient in this gel is (S)-3-(4-acetamidophenyl)-2-methoxypropanoic acid, which is also known by several other names, including RGR-1999AC, 3-(4-acetamidophenyl)-2-(S)-methoxypropionic acid, and NAC-GED-0507[1].

How Does It Work?

While the exact mechanism of action is not fully described in the provided information, topical acne treatments generally work by reducing inflammation, killing acne-causing bacteria, or helping to unclog pores. This new gel is applied directly to the skin, targeting the areas affected by acne[1].

Effectiveness

The effectiveness of N-Acetyl-GED-0507-34-LEVO Gel is being evaluated in clinical trials. Researchers are looking at several factors to determine how well it works, including:

  • Changes in the total number of acne lesions (both inflammatory and non-inflammatory)[1]
  • Improvement in the Investigator’s Global Assessment (IGA) score, which is a way to measure the overall severity of acne[1]
  • Changes in the number of inflammatory lesions (such as pimples and pustules) and non-inflammatory lesions (like blackheads and whiteheads)[2]

These studies are comparing the gel to a placebo (a gel without the active ingredient) to see how much better it works[1].

Safety and Side Effects

As with any new medication, researchers are carefully monitoring the safety of N-Acetyl-GED-0507-34-LEVO Gel. They are looking at:

  • Any side effects that occur during treatment[3]
  • How well patients tolerate the gel, including any irritation at the application site[3]
  • Changes in vital signs and laboratory test results[3]

Common side effects of topical acne treatments can include redness, dryness, or irritation of the skin where the gel is applied. However, the specific side effects of this new gel are still being studied[3].

Who Can Use This Treatment?

The clinical trials for N-Acetyl-GED-0507-34-LEVO Gel are including a wide range of people with acne vulgaris:

  • Males and females aged 9 to 50 years old[1]
  • People with moderate to severe acne on their face[1]
  • Some studies are also looking at people with acne on their trunk (upper back, shoulders, and chest)[1]

However, there are some people who cannot participate in the studies, such as those with other skin conditions, pregnant or breastfeeding women, or people with certain medical conditions[1].

How to Use the Gel

In the clinical trials, N-Acetyl-GED-0507-34-LEVO Gel is being applied once daily to the affected areas of skin[1]. The exact instructions for use, such as how much gel to apply or what time of day to use it, would be provided by a healthcare provider if the gel becomes available for general use.

Long-Term Use

One of the studies is looking at the long-term use of N-Acetyl-GED-0507-34-LEVO Gel for up to 52 weeks (one year)[3]. This study will help researchers understand:

  • How safe the gel is when used for a long time[3]
  • Whether the gel continues to be effective over time[3]
  • Any long-term effects on quality of life for people using the gel[3]

Impact on Quality of Life

Acne can have a significant impact on a person’s quality of life, affecting self-esteem and social interactions. The researchers are using questionnaires called the Dermatology Life Quality Index (DLQI) and Children’s Dermatology Life Quality Index (C-DLQI) to understand how this new treatment might improve the lives of people with acne[2][3].

In conclusion, N-Acetyl-GED-0507-34-LEVO Gel is a promising new treatment for acne vulgaris that is currently being studied in clinical trials. While more research is needed to fully understand its effectiveness and safety, it may offer a new option for people struggling with acne in the future.

Aspect Details
Drug Name (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid (N-Acetyl-GED-0507-34-Levo gel 5%)
Condition Treated Acne vulgaris (facial and truncal)
Patient Age Range 9 to 50 years
Application Method Topical, once daily
Trial Durations 12 weeks (two studies), up to 52 weeks (long-term study)
Primary Outcomes Changes in lesion counts, improvements in IGA/PGA scores, safety assessments
Secondary Outcomes Quality of life measures, long-term efficacy and safety
Key Exclusions Other forms of acne, need for systemic treatment, pregnancy, recent use of other acne treatments

FAQ

  • What is the purpose of these clinical trials? The main purpose of these clinical trials is to evaluate the safety and effectiveness of (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid gel, also known as N-Acetyl-GED-0507-34-Levo gel 5%, in treating acne vulgaris when applied once daily.
  • Who can participate in these trials? The trials generally include male and female patients aged 9 to 50 years with facial acne vulgaris. Some studies also include patients with truncal acne. Specific criteria for acne severity and lesion count are used to determine eligibility.
  • How long do the treatments last in these trials? The treatment durations vary across the trials. Two studies last for 12 weeks, while the long-term safety study extends up to 52 weeks of treatment.
  • What are the main outcomes being measured in these trials? The trials measure various outcomes, including changes in acne lesion counts, improvements in global assessment scores, quality of life, and safety aspects such as adverse events and local skin reactions.
  • Are there any specific exclusion criteria for these trials? Yes, there are several exclusion criteria. These include having other forms of acne besides acne vulgaris, requiring systemic acne treatment, having certain medical conditions, pregnancy or breastfeeding, and recent use of other acne treatments.

Ongoing Clinical Trials on (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid

  • Study of N-Acetyl-GED-0507-34-LEVO 5% gel applied daily for 12 weeks in patients with acne vulgaris

    Not recruiting

    3 1
    Investigated drugs:
    Italy Poland Spain

  • Study of N-Acetyl-GED-0507-34-LEVO gel 5% applied daily for treating acne vulgaris

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Spain

  • Title: Long-term safety study of N-Acetyl-GED-0507-34-LEVO gel 5% applied to the skin for patients with acne vulgaris

    Not recruiting

    3 1 1
    Investigated drugs:
    Italy Poland Spain

Glossary

  • Acne vulgaris: A common skin condition characterized by the appearance of pimples, blackheads, and whiteheads, typically on the face, chest, and back.
  • Topical: Applied directly to the skin.
  • Investigator's Global Assessment (IGA): A scale used by researchers to evaluate the overall severity of acne.
  • Physician Global Assessment (PGA): A scale used by doctors to evaluate the overall severity of acne, particularly on the trunk area.
  • Inflammatory lesions: Acne spots that are red and swollen, such as papules and pustules.
  • Non-inflammatory lesions: Acne spots that are not swollen or red, such as blackheads and whiteheads (also called open and closed comedones).
  • Adverse Event (AE): Any unfavorable medical occurrence in a patient during a clinical trial, whether or not it is related to the treatment being studied.
  • Treatment-Emergent Adverse Event (TEAE): An adverse event that appears or worsens after the start of treatment in a clinical trial.
  • Dermatology Life Quality Index (DLQI): A questionnaire that measures how much a skin problem affects a person's quality of life.
  • Children's Dermatology Life Quality Index (C-DLQI): A version of the DLQI designed specifically for children aged 4 to 16 years.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-n-acetyl-ged-0507-34-levo-gel-for-patients-with-acne-vulgaris/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-n-acetyl-ged-0507-34-levo-gel-for-patients-with-acne-vulgaris/
  3. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-n-acetyl-ged-0507-34-levo-gel-for-patients-with-acne-vulgaris/